Search
Dr Rakesh Popat

Dr Rakesh Popat

Haematology 04432920

  • Bupa Platinum consultant
  • Fee assured
  • Open Referral network
Overview
Bupa Platinum consultant
Fee assured
Open Referral network

Specialises in

  • Haemato-oncology

Offers

  • Video and telephone consultations

About me

Dr Rakesh Popat is a Consultant Haematologist and Associate Professor with specialist expertise in Multiple Myeloma. He is skilled in managing all aspects of multiple myeloma and has particular experience with novel treatments including immunotherapies such as CAR-T cell therapy and new antibody approaches. His NHS base is at University College Hospital, London where he leads the Myeloma Clinical Trials Program and the Cancer trials portfolio at the NIHR UCLH Clinical Research Facility.
Dr Popat is active both nationally and internationally in developing new treatments for myeloma. He is the Chair of the UK Myeloma Research Alliance and on the leadership boards of the UK Myeloma Forum, the European Myeloma Network and is a member of the International Myeloma Working Group (IMWG).
As part of his training he completed a PhD in novel treatments for Myeloma and was awarded a Fellowship to attend the Dana Farber Cancer Institute, Boston USA to gain further experience.

Areas of interest

Multiple myeloma all aspects, with a specific interest in new treatments

Medical secretaries

About me
My qualifications & training
My private practice
Consultant's practices
Information for healthcare professionals

Information for healthcare professionals (Bupa patients only, last 12 months)

Procedures completed

Report this page Edit details Print page

The information contained on Finder is submitted by consultants, therapists and healthcare services, and is declared by these third parties to be correct and compliant with the standards and codes of conduct specified by their relevant regulatory body. Bupa cannot guarantee the accuracy of all of the information provided.

You can find out more about the information on Finder and our website terms of use.